000050157 000__ 03013nam\a2200421\i\4500 000050157 001__ 50157 000050157 003__ SzGeWIPO 000050157 005__ 20241024004426.0 000050157 006__ m eo d 000050157 007__ cr bn |||m|||a 000050157 008__ 241007s2024\\\\enk\\\\\ob\\\\000\0\eng\d 000050157 0247_ $$a10.1093/jiplp/jpae044$$2doi 000050157 035__ $$a(OCoLC)1463455616 000050157 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL 000050157 041__ $$aeng 000050157 24500 $$aCan you patent the sun? Towards a sui generis inclusive right to manage the relationship between intellectual property and Commons. 000050157 264_1 $$aOxford, UK :$$bOxford University Press,$$c2024. 000050157 300__ $$a1 online resource (pages 705-716) 000050157 336__ $$atext$$2rdacontent 000050157 337__ $$acomputer$$2rdamedia 000050157 338__ $$aonline resource$$bcr$$2rdacarrier 000050157 4901_ $$aIntellectual Property Law & Practice,$$x1747-1540 ;$$v19, 9, 2024 000050157 520__ $$aThis paper, by adopting the Covid-19 vaccine as a case study, argues that some pharmaceutical drugs should be considered as Commons, ie goods that are managed and owned by the public at large, and not as private property—exclusivity—of pharmaceutical companies. The reasons of such a strong argument are, on the one side, the conspicuous public-funding contribution to develop Covid-19 vaccines and other essential life-saving treatments, and, on the other side, the search for a human and equity-oriented Global Health Security. It is true that, from a legal perspective, vaccines can be patented, leading to questionable practices in the pharmaceutical industry, such as patent thickets. However, an alternative and fairer path, which would result in the theorization of a Commons for the vaccine, can be pursued. In particular, the actual types of Commons in the IP law field—the public domain, exceptions/limitations to patents and open innovation instruments such as IP pledges—present some issues in relation to enforceability. By forwarding the concept of ‘negative spaces’ to the patent realm, these spaces should not only claim to not enforce IP but also be able to ‘enforce that non-enforcement’. Therefore, this paper, by building on the work of the author Dusollier, advances the idea that from the inclusivity, which is the typical feature of every Commons, a sui generis inclusive right can be envisaged and applied in the context of the vaccine, by rethinking the relationship between IP and Commons. 000050157 542__ $$fhttps://academic.oup.com/pages/using-the-content/citation 000050157 590__ $$aPublished online: 30-Apr-24 000050157 650_4 $$aCOVID-19 pandemic. 000050157 650_0 $$aPharmaceutical policy. 000050157 650_0 $$aVaccines. 000050157 650_0 $$aIntellectual property. 000050157 650_0 $$aPatents. 000050157 650_0 $$aIntellectual property. 000050157 650_0 $$aCopyright. 000050157 7001_ $$aCifrodelli, Gabriele,$$eauthor. 000050157 7731_ $$tIntellectual Property Law & Practice,$$wJIPLP 000050157 830_0 $$aIntellectual Property Law & Practice,$$v19, 9, 2024. 000050157 85641 $$uhttps://doi.org/10.1093/jiplp/jpae044$$yJournal homepage 000050157 904__ $$aJournal Article 000050157 980__ $$aJIPLP